EBOS Leadership Transition

Wednesday 19th February 2025

EBOS Group Limited (“EBOS” or “the Group”) today announces that John Cullity will retire as Chief Executive Officer (CEO), effective 30 June 2025. EBOS is also pleased to announce that the Board has appointed Adam Hall as his successor, effective 1 July 2025.

Adam Hall is a highly accomplished global executive with a strong track record in strategic growth, mergers and acquisitions, and operational excellence. Most recently, as Group Executive and President – Asia for Orica Limited, he successfully led significant growth in earnings and scale, while driving innovation and efficiency. Prior to Orica, he held senior executive roles at CF Industries and Bunge in the USA, United Kingdom and Asia.

EBOS Chair, Liz Coutts, said: “We are delighted to appoint Adam as our next CEO. Adam brings deep experience in driving operational efficiency and executing transformative M&A, having led announced transactions worth over US$20 billion in the past decade. His leadership will be instrumental as EBOS continues to pursue its growth ambitions. We look forward to working with him to continue to drive our strong growth and seize new opportunities.”

“John has been a driving force behind EBOS’ success, leading the Group through significant growth. Under his leadership, EBOS has delivered total shareholder returns of 168%, significantly outperforming the market.(1)

“Beyond the results, John has shaped EBOS into the company it is today — expanding our reach, strengthening our businesses across New Zealand, Australia, and Southeast Asia, and positioning us as a leader in healthcare and animal care. On behalf of the Board, I sincerely thank John for his outstanding contribution and wish him the very best in his well-earned retirement.”

Speaking on his appointment, Adam Hall said: “It’s a privilege to join this exceptional team, who have driven EBOS to become a clear leader across the diverse segments in which it operates. EBOS has delivered strong and consistent performance, and I look forward to working with the Board and the Executive Leadership Team to create further growth and innovation in the years ahead.”

Outgoing CEO, John Cullity, said: “My time at EBOS has been an incredible journey. Since joining as CFO in 2009, and later as CEO, I’ve had the privilege of working with exceptional people to grow the Group into what it is today. Over the past decade, we have completed over 20 strategic acquisitions that have strengthened our core businesses while expanding into new sectors, including medical technology.

“I want to extend my gratitude to our Chair, Liz Coutts, the Board, the Executive Leadership Team, and our 5,200 employees across New Zealand, Australia, and Southeast Asia. Their dedication to serving our communities is inspiring, and I am proud of what we have achieved together.”

Incoming CEO Contract

A summary of Adam Hall’s employment contract as incoming CEO is attached. He will be based in Melbourne, Australia.

(1) The TSR calculation uses the NZX share price and NZD dividends and is measured from the closing share price on the last trading day prior to Mr Cullity’s appointment as CEO on 1 April 2018 to the closing share price on 18 February 2025.

EBOS Leadership Transition

Comments from our readers

No comments yet